Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin add-on for social functioning in schizophrenia spectrum disorders
2023-509433-40-00Phase 2Authorised
- Sponsor
- Central Institute of Mental Health
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and Primary Psychotic Disorder comparing Oxytocin add-on with Placebo add-on (2 arms). Primary endpoint: Change in Personal and Social Performance Scale. Planned start Aug 2024; status: authorised.
02
Drugs
oxytocin
03
Conditions
schizophreniaPrimary Psychotic Disorder
Beyond the preview
Go deeper on 2023-509433-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509433-40-00.